Stocks Biogen Inc

  • Cramer: Biogen Idec's Profit Pipeline

    Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.

  • market-insider-stocks-to-watch-200.jpg

    Take a look at some of Monday morning's early movers:

  • ”Stick with what’s working.” Money pros have been saying that for quite a while. In other words, when you put money to work, pick stocks that are leaders not laggards – buy high and sell higher. That’s the trade that has paid. However, with some leaders advancing 50 percent or more over only a year, investors are starting to wonder how much upside can be left. Given the outperformance, should you remain bullish on these S&P overachievers? Or is the trading thesis getting a little long in the too

    With some leading stocks advancing 50% or more over a period of only 1 year, investors are starting to wonder how much upside can possibly be left.

  • Cramer makes the call on viewers' favorite stocks.

  • A partnership with one of the world’s largest biotech companies means a strong year ahead for Isis Pharmaceuticals, CEO Stanley Crooke said Wednesday on “Fast Money.”

  • The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.

  • Best Performing S&P Stock Number: 4

    Sharing perspective on the best trades in 2011; including Visa and Mastercard, with Greg Smith, Sterne Agee analyst.

  • stock_chart_2_200.jpg

    The two biggest gainers in the benchmark S&P 500 this year are in the oil and natural gas industry. Political instability among Middle Eastern oil countries and new drilling sites and technologies here at home are raising the prospects for growth, reports TheStreet.com.

  • finance_broker_desk2_200.jpg

    Ten companies on the benchmark S&P 500 Index in the health-care and aerospace and defense industry have gained as much as 61 percent this year as the third quarter played host to a tumultuous 2011 for the stock market, reports TheStreet.com.

  • Carl Icahn

    Forest Laboratories said it won backing from proxy advisory firm ISS for all 10 of its board nominees in a proxy battle with billionaire investor Carl Icahn.

  • Stocks clawed back from session lows ahead of a crucial vote in Washington on the debt deal, but still ended lower Monday following a dismal manufacturing report in addition to renewed worries over some euro zone countries.

  • amerigroup_logo2_200.jpg

    Amerigroup will release second-quarter figures on Friday before the bell. In the past 8 quarters, the company's shares rose 2.34 percent, on average, thirteen days after the company reported its quarterly results.

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Dr. Mark Schoenebaum, #1 ranked analyst from the ISI Group reveals his favorite stock in the biotech space. Get all the details, now!

  • Here is a look at the best-performing stocks in the top-performing sectors year-to-date.

  • Following are moves you might have missed. Find out why shares of Biogen and Travelers popped while Chipotle dropped.

  • earnings_central_badge.jpg

    What follows is a roundup of corporate earnings reports for Thursday, April 21.

  • It's a big week for biotech earnings as the world's biggest biotech company, Amgen, reports after the bell Wednesday. How should you position?

  • Stocks closed narrowly mixed in thin trading Monday despite a flurry of M&A activity as investors cautiously awaited the start of earnings season. Travelers gained, while Chevron fell.

  • Stocks traded lower in thin trading Monday amid a lack of economic news and as investors cautiously awaited the start of earnings season.  Travelers rose, while Chevron fell.